Physician profile
David C Simon
NPI 1205930302
$209.29
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $32.72 | 2019 | |
| Shire North American Group INC | $30.39 | 2019 | |
| Novo Nordisk INC | $24.74 | 2019 | |
| Genentech USA, INC. | $24.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.46 | 2019 | |
| Ethicon US, LLC | $17.20 | 2019 | |
| Merck Sharp & Dohme LLC | $17.02 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.53 | 2019 | |
| Allergan, INC. | $13.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.